REG - EKF Diagnostics Hldg - Acquisition of assets from Beep Insights

EKF Diagnostics HoldingsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260413:nRSM0560Aa&default-theme=true

RNS Number : 0560A  EKF Diagnostics Holdings PLC  13 April 2026

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Acquisition of technology assets from Beep Insights AB

Real-time glucose and lactate tracking for sport's performance monitoring

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics
business, announces that it has signed an asset purchase agreement with Sweden
based Beep Insights AB ("Beep Insights") in relation to its Beep Insights
Technology, an IOS and Android software application that combines data from
sports performance wearables connected via Bluetooth with real-time glucose
and lactate tracking to give personalised metrics to improve sport's
performance training.

 

The assets that have been acquired will strengthen EKF's Sports Performance
product range, specifically the Lactate Scout Sport
(https://www.ekfdiagnostics.com/point-of-care/sports/lactate-scout-sport/) ,
which is already compatible with the Beep Insights application.(a hand-held
lactate analyzer).

 

EKF has been working with Peter Alex, CEO of Beep Insights, and his team to
integrate the Beep Insights Technology

from their software application to better determine lactate threshold in a
more accessible way and improve sports training outcomes. Following the asset
purchase, Peter Alex will join the EKF team and will look into developing the
use of AI within performance training and how this can be integrated into the
Beep Insights Technology now owned by EKF. Peter has a degree in Cognitive
Science and a Masters in Interaction and Design in Engineering.

 

Commenting, Gavin Jones, Chief Executive Officer, said: "Whilst working with
Beep Insights we have been highly impressed with how well their data handling
application seamlessly connects with our handheld Lactate Scout Sport device,
enabling, fast and accurate lactate threshold testing for sports performance
athletes at all levels. The acquisition of this technology is an exciting step
forward for EKF's Sports Performance division as we look to enable athletes of
all abilities access to data to drive improved training outcomes."

 

The person responsible for arranging the release of this Announcement

on behalf of the Company is Gavin Jones, Chief Executive Officer.

 

 EKF Diagnostics Holdings plc                                www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                               via Walbrook PR
 Gavin Jones, Chief Executive Officer

 Singer Capital Markets (Nominated Adviser & Broker)                                       Tel: +44 (0)20 7496 3000
 Phil Davies / Patrick Weaver

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes
 ●    Life Sciences services provide specialist manufacture of enzymes and custom
      products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQIMMITMTIBBLF



            Copyright 2019 Regulatory News Service, all rights reserved